Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
CYAD (Celyad Oncology SA) provides a centralized hub for tracking developments in clinical-stage cell therapies and immuno-oncology innovations. This resource aggregates essential updates including trial progress, regulatory milestones, and strategic partnerships critical for evaluating the company's position in cancer treatment research.
Investors and researchers will find curated press releases detailing CYAD's NKR-T cell programs, manufacturing advancements, and collaborative initiatives with institutions like Dartmouth College. The collection emphasizes factual reporting on phase transitions, financial disclosures, and operational updates without speculative commentary.
Content spans clinical trial authorizations, intellectual property developments, and executive leadership changes. Regular updates ensure stakeholders maintain current awareness of CYAD's progress in translating cell-based therapies from laboratory research to clinical applications.
Bookmark this page for streamlined access to verified CYAD developments. Combine periodic reviews with real-time monitoring for comprehensive analysis of the company's evolving role in advanced cancer treatment solutions.
Celyad Oncology (CYAD) received a Bid Price Notice from Nasdaq on April 19, 2023, indicating its American Depositary Shares (ADSs) were below the $1.00 minimum closing bid price for 30 consecutive business days. The Company has until October 16, 2023, to regain compliance by maintaining a price of at least $1.00 for ten consecutive days. If compliance is not achieved, the ADSs may be transferred to Nasdaq Capital Market or subjected to delisting. Additionally, on March 31, 2023, Celyad received a Stockholders’ Equity Notice from Nasdaq for not meeting the $10 million stockholders’ equity requirement, reporting approximately $4.6 million as of December 31, 2022. The Company has until May 15, 2023, to submit a compliance plan. Despite these notices, Celyad states that its business operations remain unaffected.
Celyad Oncology (Euronext & Nasdaq: CYAD) received a notice from Nasdaq on
